Asarina Pharma AB (publ) Share Price Nasdaq Stockholm
Equities
SE0011641794
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 21.03M 226M 1.66B |
---|---|---|---|---|---|
Net income 2021 | -31M -333M -2.45B | Net income 2022 | -13M -140M -1.03B | EV / Sales 2021 | - |
Net cash position 2021 | 16.42M 176M 1.3B | Net cash position 2022 | 13.58M 146M 1.07B | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.15
x | P/E ratio 2022 |
-1.31
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.98% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 31/12/15 |
Director of Finance/CFO | 69 | 31/03/17 | |
Public Communications Contact | 62 | 31/12/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 31/12/17 |
Public Communications Contact | 62 | 31/12/10 | |
Marianne Kock
BRD | Director/Board Member | 69 | 31/12/17 |
1st Jan change | Capi. | |
---|---|---|
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.23% | 22.28B | |
-5.61% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |